Butantan Institute

This study tested a single-dose chikungunya vaccine (VLA1553) in about 750 teenagers aged 12 to 17. The goal was to see if the vaccine safely produces enough antibodies to protect against the virus. Participants received either the vaccine or a placebo, and their immune responses…

This completed Phase 4 trial tested whether the Butantan Institute's seasonal flu vaccine is as safe and effective as the Sanofi vaccine. A total of 632 Brazilian adults aged 18 to 69 received one of the two vaccines. Researchers measured immune response through blood tests and t…

This study tested a new dengue vaccine called V181 against an existing one (Butantan-DV) in 1,364 healthy adults aged 18 to 50 in Brazil. The goal was to see if V181 is as safe and triggers a similar immune response. Results showed V181 was safe and produced comparable antibody l…

This completed Phase 3 trial tested a quadrivalent (four-strain) influenza vaccine from Instituto Butantan in over 1,300 healthy infants and children aged 6 to 35 months. The study compared the immune response and safety of two doses (0.25ml and 0.50ml) against standard trivalent…